Friday, 24 April 2026 — Publication BB Biotech Interim Report Q1 2026 To the report

Friday, 24 April 2026 — Publication BB Biotech Interim Report Q1 2026 To the report

Your browser is out-of-date!

Update your browser to view this website correctly.

1Cookies

2Disclaimer

Current market commentary with Dr. Daniel Koller, Head Investment Management Team BB Biotech at Bellevue Asset Management.

«Cancer medicine improves the chances of a cure»

Current market commentary with Dr. Daniel Koller, Head Investment Management Team BB Biotech at Bellevue Asset Management.
09.12.2021 - Daniel Koller